Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Executive Summary
Trade associations representing largely brand manufacturers in the U.S. and Europe want FDA to release guidance on biosimilars before approving any applications, even though the law was written so the agency does not have to wait for guidance to conduct reviews.
You may also be interested in...
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Rising concerns among generic firms about how FDA will interpret biosimilar exclusivity provisions may have escalated due to fears about the consequences of increased congressional scrutiny of the new pathway.
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Rising concerns among generic firms about how FDA will interpret biosimilar exclusivity provisions may have escalated due to fears about the consequences of increased congressional scrutiny of the new pathway.
Biosimilars On The Horizon: How Much Will FDA Look To The East?
Europe's pathway for follow-on biologics has selling points for both brand and generic firms, but FDA will chart its own course - even as it mulls accepting European data.